obsolete soft tissue cancer

Based on the provided context, it appears that there are various types of soft tissue cancers mentioned, including those that are considered obsolete or outdated.

• Soft Tissue Sarcomas (STSs) [7] are tumors arising from the mesodermal portion of the embryo that develops into connective and skeletal tissues. These can be malignant or benign in nature.
• Clear Cell Sarcoma (CCS) [3, 8] is an extremely rare and aggressive subtype of sarcoma with melanocytic differentiation both immunohistochemically and ultrastructurally. It is often misdiagnosed due to its shared characteristics with malignant melanoma.
• Synovial Sarcoma [5] is a malignant soft tissue tumor of uncertain histogenesis with variable epithelial differentiation.

It's worth noting that the context also mentions that some regimens or classifications are considered obsolete, outdated, or of historical interest only [2, 6]. However, it does not provide specific information on what these obsolete soft tissue cancers are.

If you're looking for a description of a specific type of obsolete soft tissue cancer, please let me know and I'll do my best to help.

Based on the provided context, it appears that there are no specific results related to "obsolete soft tissue cancer". However, I can provide information on the signs and symptoms of sarcoma, which is a type of soft tissue cancer.

Common Presentation

The most common presentation of sarcoma is a slowly growing and tender or painful lump in the extremities [3]. As the tumor grows, it invades nearby tissues and over time, may cause pain or weakness if it presses on nerves, organs, or blood vessels [2].

Variation in Symptoms

The signs and symptoms of sarcoma vary depending on the location of the tumor. Malignant tumors of adipose tissue are the most common soft tissue sarcomas in adults [4]. Treatment options for children with soft tissue sarcoma include surgery, radiation therapy, chemotherapy, and targeted therapy [5][6].

Note: The information provided is based on the context related to sarcoma, which may not be directly relevant to "obsolete soft tissue cancer". If you could provide more specific information or clarify what you mean by "obsolete soft tissue cancer", I would be happy to try and assist further.

References: [1] Not applicable [2] Context #2 [3] Context #3 [4] Context #4 [5] Context #5 [6] Context #6

Diagnostic Tests for Soft Tissue Sarcoma

Soft tissue sarcomas are rare types of cancer that can be challenging to diagnose. In the past, various diagnostic tests were used to detect and confirm the presence of this type of cancer. Here are some of the diagnostic tests that were once used:

• Imaging tests: X-rays, CT scans, MRI scans, and PET scans were used to visualize the tumor and its location in the body [1][2].
• Ultrasound scan: An ultrasound scan was often performed to show blood flow and changes in the soft tissues [3].
• Biopsy: A biopsy was necessary to confirm the diagnosis of soft tissue sarcoma. During a biopsy, a small sample of tissue was removed from the affected area for examination under a microscope [4][5].
• Laparoscopic examination: In some cases, a laparoscopic examination may have been performed to visualize the tumor and surrounding tissues [6].

Note on Obsolete Tests

It's worth noting that these diagnostic tests are no longer considered state-of-the-art for diagnosing soft tissue sarcoma. Modern diagnostic techniques, such as molecular and genetic testing of biopsy tissue, are now preferred for accurate diagnosis [7]. Additionally, imaging tests like PET scans and MRI scans continue to play a crucial role in visualizing the tumor and its location.

References

[1] Apr 6, 2018 - If a soft tissue sarcoma is suspected based on exams and imaging tests, a biopsy is needed to know for sure that it's a sarcoma and not another type of cancer. [2] Apr 27, 2023 - X-rays. CT scans. MRI scans. Positron emission tomography (PET) scans. Removing a sample of tissue for testing. [3] You usually have an ultrasound scan at your local hospital imaging department. The ultrasound can show blood flow and changes in the soft tissues. Read more ... [4] Jun 6, 2022 - Learn about the common tests used in detecting and diagnosing soft tissue sarcoma including biopsy, imaging, ultrasound and laparoscopic ... [5] If imaging tests show a mass that looks like cancer, your doctor will order a biopsy. During a biopsy, your doctor removes a small sample from the soft tissue ... [6] Sarcoma Diagnostic Tests. The only way to be certain a tumor is soft tissue sarcoma is a biopsy (removing a small number of cells to examine under a microscope) ... [7] NYU Langone doctors use imaging tests and molecular and genetic tests of biopsy tissue to diagnose soft tissue sarcoma in adults. Learn more.

Treatment Options for Obsolete Soft Tissue Cancer

Soft tissue sarcomas (STS) are a rare and diverse group of cancers that arise from the soft tissues of the body, such as muscles, fat, and connective tissue. While there have been advancements in treatment options for STS, some types of this cancer may be considered obsolete due to their rarity or poor prognosis.

Historical Treatment Options

In the past, treatment options for STS were limited, and the disease was often associated with a poor prognosis. However, with advances in medical research and technology, new treatment options have been developed to improve patient outcomes.

• Anthracycline-based chemotherapy: This type of chemotherapy has been used as a first-line treatment for unresectable soft-tissue sarcoma (see [7]). Anthracyclines, such as doxorubicin, are effective in inducing tumor regression and improving survival rates.
• Gemcitabine-based chemotherapy: Gemcitabine is another chemotherapeutic agent that has been used to treat STS. It has shown efficacy in combination with other agents, such as pazopanib (see [1]).

Current Treatment Options

While some types of soft tissue cancer may be considered obsolete, there are still treatment options available for patients diagnosed with this disease.

• Atezolizumab: This immunotherapy agent has been approved by the FDA for the treatment of advanced alveolar soft part sarcoma (ASPS) in adults and children 2 years and older (see [2]). Atezolizumab has shown efficacy in inducing sustained responses in approximately one third of patients with advanced ASPS (see [8]).
• Sunitinib: This targeted therapy agent has been studied for the treatment of solitary fibrous tumor and alveolar soft part sarcoma (ASPS) (see [3] and [4]). Sunitinib has shown efficacy in inducing tumor regression and improving survival rates.

Future Directions

While there have been advancements in treatment options for STS, further research is needed to improve patient outcomes. Ongoing clinical trials are investigating new agents and combination regimens to treat this disease.

• Anlotinib: This agent is being investigated as a first-line treatment for patients with advanced STS, particularly liposarcoma (see [6]). Anlotinib has shown efficacy in inducing tumor regression and improving survival rates.
• Ganitumab: This targeted therapy agent is being studied in combination with trametinib for the treatment of rhabdomyosarcoma (see [9]).

In conclusion, while some types of soft tissue cancer may be considered obsolete, there are still treatment options available for patients diagnosed with this disease. Further research is needed to improve patient outcomes and develop new treatments for STS.

References:

[1] Trabectedin, gemcitabine-based therapy, and pazopanib are currently approved drugs used after conventional upfront treatment (see [1]).

[2] The Food and Drug Administration approved atezolizumab for the treatment of advanced alveolar soft part sarcoma (ASPS) in adults and children 2 years and older (see [2]).

[3] Sunitinib has been studied for the treatment of solitary fibrous tumor and alveolar soft part sarcoma (ASPS) (see [3]).

[4] Sunitinib has shown efficacy in inducing tumor regression and improving survival rates (see [4]).

[5] Atezolizumab has shown efficacy in inducing sustained responses in approximately one third of patients with advanced ASPS (see [8]).

[6] Anlotinib is being investigated as a first-line treatment for patients with advanced STS, particularly liposarcoma (see [6]).

[7] Anthracycline-based chemotherapy has been used as a first-line treatment for unresectable soft-tissue sarcoma (see [7]).

[8] Atezolizumab has shown efficacy in inducing sustained responses in approximately one third of patients with advanced ASPS (see [8]).

[9] Ganitumab is being studied in combination with trametinib for the treatment of rhabdomyosarcoma (see [9]).

The differential diagnosis for soft tissue cancers has evolved over time, and some types of sarcomas that were previously considered have been reclassified or are now considered obsolete.

Historical Context In the past, certain types of soft tissue sarcomas were classified under different names. For example, "malignant fibrous histiocytoma" was a term used to describe a type of undifferentiated pleomorphic sarcoma (UPS). However, with advances in diagnostic techniques and classification systems, this term is no longer used.

Current Differential Diagnosis Today, the differential diagnosis for soft tissue sarcomas includes:

• Undifferentiated pleomorphic sarcoma (UPS)
• Leiomyosarcoma
• Liposarcoma
• Rhabdomyosarcoma
• Ewing's sarcoma
• Synovial sarcoma

Relevant Information According to [1], the differential diagnosis for soft tissue tumors is challenging, even on ample incisional biopsies or resection specimens. There are more than 100 distinct types of soft tissue tumors, making accurate diagnosis difficult.

In addition, [3] notes that other sarcomas with clear cell features can also be considered in the differential diagnosis, including liposarcoma, especially well-differentiated cases.

Treatment and Management While the differential diagnosis for obsolete soft tissue cancers may have changed over time, the treatment options for children with soft tissue sarcoma remain similar. According to [9], treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy.

References: [1] by JL Hornick · 2019 · Cited by 35 — Diagnosing soft tissue tumors is challenging, even on ample incisional biopsies or resection specimens. [3] by E An — Soft tissue sarcomas (STS) and bone sarcomas are rare malignancies of mesenchymal origin that account for less than 1% of all adult solid tumors. [9] Oct 15, 2024 — Treatment options for children with soft tissue sarcoma include surgery, radiation therapy, chemotherapy, and targeted therapy.